Pricing Log in Create free account

Denali Therapeutics Inc. (DNLI) vs Viridian Therapeutics, Inc. (VRDN)

Denali Therapeutics Inc. and Viridian Therapeutics, Inc. are both Biotechnology companies. Denali Therapeutics Inc. and Viridian Therapeutics, Inc. are of similar size ($3.2B and $3.2B). Viridian Therapeutics, Inc. grew revenue faster over the last twelve months: −62.8% against −93.4%. Denali Therapeutics Inc. has the higher net margin (−1,388.2% vs −1,724.1%) and the lower return on invested capital (−80.0% vs 0.00%). Across the 18 metrics below, Viridian Therapeutics, Inc. leads on 13 and Denali Therapeutics Inc. on 5.

Valuation

Metric DNLI VRDN Biotechnology median
P/E n/m n/m 10.26
P/S 165.44 117.81 9.18
P/B 4.04 5.49 2.05
Price to free cash flow n/m n/m 24.81
EV/EBITDA n/m n/m 0.65
EV/Sales 142.89 91.03 8.98
Earnings yield (8.69%) (11.73%) (34.89%)
Free cash flow yield (12.01%) (11.08%) (24.52%)

Profitability

Metric DNLI VRDN Biotechnology median
Gross margin 98.74% 100.00% 65.16%
Operating margin (2,348.95%) (1,781.38%) 0.00%
Net margin (1,388.24%) (1,724.06%) 0.00%
Free cash flow margin (1,986.81%) (1,305.42%) 0.00%
Return on equity (33.94%) 0.00% (50.12%)
Return on assets (27.20%) (56.49%) (45.60%)
Return on invested capital (80.00%) 0.00% 0.00%

Growth

Metric DNLI VRDN Biotechnology median
Revenue growth (TTM) (93.40%) (62.83%) 6.26%
EPS growth (last fiscal year) (15.56%) (8.14%) 29.88%
Revenue growth, 5-year CAGR 20.67% 132.18% 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric DNLI VRDN Biotechnology median
Debt to equity 0.01 0.00 0.00
Current ratio 6.21 14.46 4.89
Net debt to EBITDA 1.56 2.23 1.01

Dividend

Metric DNLI VRDN Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric DNLI VRDN Biotechnology median
Market cap 3.16b 3.23b 172.11m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack